@prefix this: <http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng> .
@prefix sub: <http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_10933> bl:category bl:Disease .
  
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_10933>;
    rdf:predicate bl:treats;
    rdf:subject <https://identifiers.org/drugbank:DB00472>;
    a rdf:Statement;
    rdfs:label "fluoxetine capsules usp are a selective serotonin reuptake inhibitor indicated for acute and maintenance treatment of major depressive disorder mdd in adult and pediatric patients aged 8 to 18 years 1 1 acute and maintenance treatment of obsessive compulsive disorder ocd in adult and pediatric patients aged 7 to 17 years 1 2 acute and maintenance treatment of bulimia nervosa in adult patients 1 3 acute treatment of panic disorder with or without agoraphobia in adult patients 1 4 fluoxetine capsules usp and olanzapine in combination acute treatment of depressive episodes associated with bipolar i disorder in adults 1 5 fluoxetine capsules usp are indicated for the acute and maintenance treatment of major depressive disorder in adult patients and in pediatric patients aged 8 to 18 years see clinical studies 14 1 the usefulness of the drug in adult and pediatric patients receiving fluoxetine for extended periods should periodically be re evaluated see dosage and administration 2 1 fluoxetine capsules usp are indicated for the acute and maintenance treatment of obsessions and compulsions in adult patients and in pediatric patients aged 7 to 17 years with obsessive compulsive disorder ocd see clinical studies 14 2 the effectiveness of fluoxetine capsules usp in long term use i e for more than 13 weeks has not been systematically evaluated in placebo controlled trials therefore the physician who elects to use fluoxetine capsules usp for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient see dosage and administration 2 2 fluoxetine capsules usp are indicated for the acute and maintenance treatment of binge eating and vomiting behaviors in adult patients with moderate to severe bulimia nervosa see clinical studies 14 3 the physician who elects to use fluoxetine capsules usp for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient see dosage and administration 2 3 fluoxetine capsules usp are indicated for the acute treatment of panic disorder with or without agoraphobia in adult patients see clinical studies 14 4 the effectiveness of fluoxetine capsules usp in long term use i e for more than 12 weeks has not been established in placebo controlled trials therefore the physician who elects to use fluoxetine capsules usp for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient see dosage and administration 2 4 when using fluoxetine capsules usp and olanzapine in combination also refer to the clinical studies section of the package insert for olanzapine and fluoxetine hydrochloride capsules fluoxetine capsules usp and olanzapine in combination is indicated for the acute treatment of depressive episodes associated with bipolar i disorder in adult patients fluoxetine capsules usp monotherapy is not indicated for the treatment of depressive episodes associated with bipolar i disorder";
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
    bl:provided_by <https://w3id.org/um/NeuroDKG>;
    bl:relation schema:TreatmentIndication .
  
  <https://identifiers.org/drugbank:DB00472> bl:category bl:Drug .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "aqwx3O5MBt/6UgUtYoLgi7x3tnv2ygQvPXRiDTUG8UPhg/n/1RfkLR7a4k+TKUNaSlaoNeD7NqevVEAeFEWiUbWKygkc8tXNwEA/nAgA0tJWTBbe66Bd6Un4zb+nqXaKvyk2YG7m0yJlW30Ok0b2Jx58fsVQMk9QIPNMpxU2IB8=";
    npx:hasSignatureTarget this: .
  
  this: dct:created "2021-06-15T18:01:37.131+02:00"^^xsd:dateTime;
    dct:creator orcid:0000-0002-1468-3557;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs> .
}